<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-07-31" updated="2020-01-02">
  <drugbank-id primary="true">DB01546</drugbank-id>
  <name>Etryptamine</name>
  <description>In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was an FDA approved antidepressant under the name Monase. However, in 1962, after the discovery of an unacceptable incidence of agranulocytosis, the development of Monase was halted and the drug was withdrawn from potential market use. &#13;
&#13;
In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's. Currently, αET is an illegal substance; however, it's activity is still under scientific investigation. &#13;
&#13;
αET is a stimulant and hallucinogen, but it is less stimulating and hallucinogenic than alpha-methyltryptamine, a closely related compound. Instead, the effects of αET, a tryptamine derivative, more closely resemble the amphetamine derived drug 3,4-methylenedioxy-N-methylamphetamine (MDMA). Similarly to MDMA, αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine. Like MDMA, increases in locomotor activity and mood elevation can be seen post administration.</description>
  <cas-number>2235-90-7</cas-number>
  <unii>GR181O3R32</unii>
  <average-mass>188.2688</average-mass>
  <monoisotopic-mass>188.131348522</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>illicit</group>
    <group>investigational</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A14397</ref-id>
        <pubmed-id>1722753</pubmed-id>
        <citation>Huang XM, Johnson MP, Nichols DE: Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase). Eur J Pharmacol. 1991 Jul 23;200(1):187-90.</citation>
      </article>
      <article>
        <ref-id>A14398</ref-id>
        <pubmed-id>7855195</pubmed-id>
        <citation>Krebs KM, Geyer MA: Behavioral characterization of alpha-ethyltryptamine, a tryptamine derivative with MDMA-like properties in rats. Psychopharmacology (Berl). 1993;113(2):284-7.</citation>
      </article>
      <article>
        <ref-id>A14399</ref-id>
        <pubmed-id>9138441</pubmed-id>
        <citation>Martinez DL, Geyer MA: Characterization of the disruptions of prepulse inhibition and habituation of startle induced by alpha-ethyltryptamine. Neuropsychopharmacology. 1997 Mar;16(3):246-55.</citation>
      </article>
      <article>
        <ref-id>A14400</ref-id>
        <pubmed-id>14048556</pubmed-id>
        <citation>STEINER WG, PSCHEIDT GR, COSTA E, HIMWICH HE: ALPHA-ETHYLTRYPTAMINE (ETRYPTAMINE): AN ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND NEUROCHEMICAL ANALYSIS. Psychopharmacologia. 1963 Jul 2;4:354-66.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L68</ref-id>
        <title>Link</title>
        <url>http://isomerdesign.com/PiHKAL/read.php?domain=tk&amp;id=11</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>α-ET TiHKAL entry • Isomer Design: http://isomerdesign.com/PiHKAL/read.php?domain=tk&amp;id=11</synthesis-reference>
  <indication>Developed in the 1960's for use as an antidepressant before market withdrawal in 1962. &#13;
</indication>
  <pharmacodynamics>αET is a stimulant and psychedelic with MDMA like physiological effects. Like MDMA, increases in locomotor activity and mood elevation can be seen post administration. [2]</pharmacodynamics>
  <mechanism-of-action>The mechanism of action responsible for its antidepressant activity  was believed to lie in its ability to inhibit monoamine oxidase, while its stimulant activity on the central nervous system appeared to result from its structural similarity to indole-based psychedelics. [5] &#13;
 &#13;
Research discovered αET to be both a monoamine oxidase inhibitor and a potent monoamine releasing agent capable of serotonergic neurotoxicity. [3]&#13;
&#13;
The ability to release serotonin was linked to αET's MDMA like properties. [2] αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine. </mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.</description>
    <direct-parent>3-alkylindoles</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Indoles and derivatives</class>
    <subclass>Indoles</subclass>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzenoids</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monoalkylamines</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Substituted pyrroles</alternative-parent>
    <substituent>3-alkylindole</substituent>
    <substituent>Amine</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary aliphatic amine</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Pyrrole</substituent>
    <substituent>Substituted pyrrole</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000188</drugbank-id>
      <name>Alpha-ethyltryptamine acetate</name>
      <unii>3RY07R55EE</unii>
      <cas-number>118-68-3</cas-number>
      <inchikey>TUQLBJAHRWROHB-UHFFFAOYSA-N</inchikey>
      <average-mass>248.3208</average-mass>
      <monoisotopic-mass>248.152477894</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">3-(2-aminobutyl)indole</synonym>
    <synonym language="english" coder="">alpha-ethyltryptamine</synonym>
    <synonym language="english" coder="">α-ethyltryptamine</synonym>
    <synonym language="english" coder="">αET</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>Monase </name>
      <company>Upjohn</company>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Biogenic Amines</category>
      <mesh-id>D001679</mesh-id>
    </category>
    <category>
      <category>Biogenic Monoamines</category>
      <mesh-id>D015306</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Indoles</category>
      <mesh-id>D007211</mesh-id>
    </category>
    <category>
      <category>Stimulants</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.55</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.81e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.43</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1-(1H-indol-3-yl)butan-2-amine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>α-ethyltryptamine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>188.2688</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>188.131348522</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCC(N)CC1=CNC2=CC=CC=C12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H16N2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C12H16N2/c1-2-10(13)7-9-8-14-12-6-4-3-5-11(9)12/h3-6,8,10,14H,2,7,13H2,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>ZXUMUPVQYAFTLF-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>41.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>59.32</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>22.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>17.13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.99</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>510 mg/L</value>
      <source>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>221</value>
      <source>Young, E.H.P.; British Patent 933,786; August 14,1963; assigned to Imperial Chemical Industries Ltd.</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.57</value>
      <source>ADME Research, USCD</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>134838</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>8367</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507084</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C06213</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D04092</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>8064</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50025198</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Alpha-Ethyltryptamine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1619758</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>